Meeting
2017 Palliative and Supportive Care in Oncology Symposium
Comparison of hydration events in patients (pts) receiving highly (HEC) or moderately (MEC) emetogenic chemotherapy treated with granisetron extended-release subcutaneous (GERSC) or palonosetron (PALO).
Authors
Jeffrey Vacirca
New York Cancer & Blood Specialists, East Setauket, NY
Jeffrey Vacirca, Dennis Caruana, George Calcanes, Michael Mosier, Ralph V. Boccia, Ali McBride
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Integration and Delivery of Palliative and Supportive Care,Communication and Shared Decision Making,Symptom Biology, Assessment, and Management,Models of Care
Sub Track
Integration and Delivery of Palliative and Supportive Care
Citation
J Clin Oncol 35, 2017 (suppl 31S; abstract 108)
DOI
10.1200/JCO.2017.35.31_suppl.108
Abstract #
108
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Antiemetic prophylaxis with NEPA: Final results of the German AKYPRO study.
First Author: Joerg Peter Schilling
Poster
2013 ASCO Annual Meeting
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
First Author: Matti S. Aapro
Poster
2020 ASCO Virtual Scientific Program
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
First Author: Matti S. Aapro
Poster
2019 ASCO Annual Meeting
Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4.
First Author: Rudolph M. Navari